Skip to content

Oruka Therapeutics, Inc. ORKA Proceeds From Atthemarket Offering Net Of Commissions

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept orka:ProceedsFromAtthemarketOfferingNetOfCommissions.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Oruka Therapeutics, Inc.'s proceeds from atthemarket offering net of commissions?
Oruka Therapeutics, Inc. (ORKA) reported proceeds from atthemarket offering net of commissions of $38.9M in Q1 2026.